Advances in the development of aptamer drug conjugates for targeted drug delivery

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 9, Issue 3, 2017, Pages

  Chen, Ke ^a   Liu, Bo ^a   Yu, Bo ^a   Zhong, Wen ^a   Lu, Yi ^a   Zhang, Jiani ^a   Liao, Jie ^a   Liu, Jun ^a,b   Pu, Ying ^a   Qiu, Liping ^b   Zhang, Liqin ^b,c   Liu, Huixia ^a   Tan, Weihong ^b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN UNIVERSITY   (China)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDES;

BIO-MARKER DISCOVERY; FACILE MODIFICATIONS; HIGH REPRODUCIBILITY; MACROMOLECULAR DRUGS; TARGETED DRUG DELIVERY; TARGETING LIGANDS; THERAPEUTIC INTERVENTION; TISSUE PENETRATIONS;

DRUG INTERACTIONS;

ANTIBODY; ANTINEOPLASTIC AGENT; APTAMER; CISPLATIN; COCAINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GOLD NANOPARTICLE; GOLD NANOROD; LIPOSOME; MONOCLONAL ANTIBODY; NANOPARTICLE; DRUG CARRIER;

BIOCOMPATIBILITY; CELL DIVISION; CONJUGATION; COST EFFECTIVENESS ANALYSIS; COVALENT BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; HUMAN; HYDROGEL; IMMUNOGENICITY; IN VITRO STUDY; INTERCALATION COMPLEX; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE; ANIMAL; CELL LINE; MEDICAL RESEARCH; MOUSE; PROCEDURES;

ANIMALS; APTAMERS, NUCLEOTIDE; BIOMEDICAL RESEARCH; CELL LINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICE;

EID: 84996956308     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1438     Document Type: Review

References (106)

1. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 2011, 3:848–883.
2. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971–3010.
3. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991, 11:26–37.
4. Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm 2015, 12:1005–1017.
5. de Figueiredo IR, Freire JM, Flores L, Veiga AS, Castanho MA. Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies. IUBMB Life 2014, 66: 182–194.
6. Guijarro-Munoz I, Compte M, Alvarez-Vallina L, Sanz L. Antibody gene therapy: getting closer to clinical application? Curr Gene Ther 2013, 13:282–290.
7. Smaglo BG, Aldeghaither D, Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 2014, 11:637–648.
8. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505–510.
9. Gallina ME, Zhou Y, Johnson CJ, Harris-Birtill D, Singh M, Zhao H, Ma D, Cass T, Elson DS. Aptamer-conjugated, fluorescent gold nanorods as potential cancer theradiagnostic agents. Mater Sci Eng C Mater Biol Appl 2016, 59:324–332.
10. Kang L, Yang B, Zhang X, Cui L, Meng H, Mei L, Wu C, Ren S, Tan W. Enzymatic cleavage and mass amplification strategy for small molecule detection using aptamer-based fluorescence polarization biosensor. Anal Chim Acta 2015, 879:91–96.
11. Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, Bawa R, Kanwar RK. Nucleic acid-based aptamers: applications, development and clinical trials. Curr Med Chem 2015, 22:2539–2557.
12. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010, 9:537–550.
13. Li W, Lan X. Aptamer oligonucleotides: novel potential therapeutic agents in autoimmune disease. Nucleic Acid Ther 2015, 25:173–179.
14. Sun H, Tan W, Zu Y. Aptamers: versatile molecular recognition probes for cancer detection. Analyst 2016, 141:403–415.
15. Xu X, Dickey DD, Chen SJ, Giangrande PH. Structural computational modeling of RNA aptamers. Methods 2016, 103:175–179.
16. Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb) 2012, 48:10472–10480.
17. Zhu Z, Song Y, Li C, Zou Y, Zhu L, An Y, Yang CJ. Monoclonal surface display SELEX for simple, rapid, efficient, and cost-effective aptamer enrichment and identification. Anal Chem 2014, 86:5881–5888.
18. Alibolandi M, Ramezani M, Abnous K, Hadizadeh F. AS1411 aptamer-decorated biodegradable polyethylene glycol-poly(lactic-co-glycolic acid) nanopolymersomes for the targeted delivery of gemcitabine to nonsmall cell lung cancer in vitro. J Pharm Sci 2016, 105:1741–1750.
19. Gijs M, Aerts A, Impens N, Baatout S, Luxen A. Aptamers as radiopharmaceuticals for nuclear imaging and therapy. Nucl Med Biol 2015, 43:253–271.
20. Meng HM, Zhang X, Lv Y, Zhao Z, Wang NN, Fu T, Fan H, Liang H, Qiu L, Zhu G, et al. DNA dendrimer: an efficient nanocarrier of functional nucleic acids for intracellular molecular sensing. ACS Nano 2014, 8:6171–6181.
21. Xing H, Zhang CL, Ruan G, Zhang J, Hwang K, Lu Y. Multimodal detection of a small molecule target using stimuli-responsive liposome triggered by aptamer-enzyme conjugate. Anal Chem 2016, 88:1506–1510.
22. Zhou C, Chen T, Wu C, Zhu G, Qiu L, Cui C, Hou W, Tan W. Aptamer CaCO3 nanostructures: a facile, pH-responsive, specific platform for targeted anticancer theranostics. Chem Asian J 2015, 10:166–171.
23. Chang YC, Yang CY, Sun RL, Cheng YF, Kao WC, Yang PC. Rapid single cell detection of Staphylococcus aureus by aptamer-conjugated gold nanoparticles. Sci Rep 2013, 3:1863.
24. Feng H, Beck J, Nassal M, Hu KH. A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One 2011, 6:e27862.
25. Gopinath SC, Hayashi K, Kumar PK. Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry. J Virol 2012, 86:6732–6744.
26. Hong KL, Sooter LJ. Single-stranded DNA aptamers against pathogens and toxins: identification and biosensing applications. Biomed Res Int 2015, 2015:419318.
27. Kowalska E, Bartnicki F, Pels K, Strzalka W. The impact of immobilized metal affinity chromatography (IMAC) resins on DNA aptamer selection. Anal Bioanal Chem 2014, 406:5495–5499.
28. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103:11838–11843.
29. Urak KT, Shore S, Rockey WM, Chen SJ, McCaffrey AP, Giangrande PH. In vitro RNA SELEX for the generation of chemically-optimized therapeutic RNA drugs. Methods 2016, 103:167–174.
30. You M, Zhu G, Chen T, Donovan MJ, Tan W. Programmable and multiparameter DNA-based logic platform for cancer recognition and targeted therapy. J Am Chem Soc 2015, 137:667–674.
31. Tang Z, Shangguan D, Wang K, Shi H, Sefah K, Mallikratchy P, Chen HW, Li Y, Tan W. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 2007, 79:4900–4907.
32. Liang H, Zhang XB, Lv Y, Gong L, Wang R, Zhu X, Yang R, Tan W. Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy. Acc Chem Res 2014, 47:1891–1901.
33. Shum KT, Zhou J, Rossi JJ. Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) 2013, 6:1507–1542.
34. Yi M, Yang S, Peng Z, Liu C, Li J, Zhong W, Yang R, Tan W. Two-photon graphene oxide/aptamer nanosensing conjugate for in vitro or in vivo molecular probing. Anal Chem 2014, 86:3548–3554.
35. Zichel R, Chearwae W, Pandey GS, Golding B, Sauna ZE. Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins. PLoS One 2012, 7:e31948.
36. Ma J, Wang MG, Mao AH, Zeng JY, Liu YQ, Wang XQ, Ma J, Tian YJ, Ma N, Yang N, et al. Target replacement strategy for selection of DNA aptamers against the Fc region of mouse IgG. Genet Mol Res 2013, 12:1399–1410.
37. Reinstein O, Yoo M, Han C, Palmo T, Beckham SA, Wilce MC, Johnson PE. Quinine binding by the cocaine-binding aptamer. Thermodynamic and hydrodynamic analysis of high-affinity binding of an off-target ligand. Biochemistry 2013, 52:8652–8662.
38. Slavkovic S, Altunisik M, Reinstein O, Johnson PE. Structure-affinity relationship of the cocaine-binding aptamer with quinine derivatives. Bioorg Med Chem 2015, 23:2593–2597.
39. Kalnins A, Thomas MN, Andrassy M, Muller S, Wagner A, Pratschke S, Rentsch M, Klussmann S, Kauke T, Angele MK, et al. Spiegelmer inhibition of MCP-1/CCR2—potential as an adjunct immunosuppressive therapy in transplantation. Scand J Immunol 2015, 82:102–109.
40. Ramaswamy V, Monsalve A, Sautina L, Segal MS, Dobson J, Allen JB. DNA aptamer assembly as a vascular endothelial growth factor receptor agonist. Nucleic Acid Ther 2015, 25:227–234.
41. Ravalli A, Rivas L, De la Escosura-Muniz A, Pons J, Merkoci A, Marrazza G. A DNA aptasensor for electrochemical detection of vascular endothelial growth factor. J Nanosci Nanotechnol 2015, 15:3411–3416.
42. Rhinehardt KL, Srinivas G, Mohan RV. Molecular dynamics simulation analysis of anti-MUC1 aptamer and mucin 1 peptide binding. J Phys Chem B 2015, 119:6571–6583.
43. Shangguan D, Cao Z, Meng L, Mallikaratchy P, Sefah K, Wang H, Li Y, Tan W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 2008, 7:2133–2139.
44. Tang J, Xie J, Shao N, Yan Y. The DNA aptamers that specifically recognize ricin toxin are selected by two in vitro selection methods. Electrophoresis 2006, 27:1303–1311.
45. Tang J, Yu T, Guo L, Xie J, Shao N, He Z. In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection. Biosens Bioelectron 2007, 22:2456–2463.
46. Jeon SH, Kayhan B, Ben-Yedidia T, Arnon R. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J Biol Chem 2004, 279:48410–48419.
47. Koch TH, Smith D, Tabacman E, Zichi DA. Kinetic analysis of site-specific photoaptamer-protein cross-linking. J Mol Biol 2004, 336:1159–1173.
48. Dai H, Ye M, Peng M, Zhou W, Bai H, Xiao X, Ma B, Zhou J, Tang S, Yao S, et al. Aptamer TY04 inhibits the growth of multiple myeloma cells via cell cycle arrest. Tumour Biol 2014, 35:7561–7568.
49. Leach JC, Wang A, Ye K, Jin S. A RNA-DNA hybrid aptamer for nanoparticle-based prostate tumor targeted drug delivery. Int J Mol Sci 2016, 17:380.
50. Liu J, Liu H, Sefah K, Liu B, Pu Y, Van Simaeys D, Tan W. Selection of aptamers specific for adipose tissue. PLoS One 2012, 7:e37789.
51. Pu Y, Liu Z, Lu Y, Yuan P, Liu J, Yu B, Wang G, Yang CJ, Liu H, Tan W. Using DNA aptamer probe for immunostaining of cancer frozen tissues. Anal Chem 2015, 87:1919–1924.
52. Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol 2014, 32:272–279.
53. Guo KT, Yan XR, Huang GJ, Xu CX, Chai YS, Zhang ZQ. Screening and characterization of DNA aptamers with hTNF-alpha binding and neutralizing activity [in Chinese]. Sheng Wu Gong Cheng Xue Bao 2003, 19:730–733.
54. Wu X, Zhao Z, Bai H, Fu T, Yang C, Hu X, Liu Q, Champanhac C, Teng IT, Ye M, et al. DNA aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition. Theranostics 2015, 5:985–994.
55. Lou X, Qian J, Xiao Y, Viel L, Gerdon AE, Lagally ET, Atzberger P, Tarasow TM, Heeger AJ, Soh HT. Micromagnetic selection of aptamers in microfluidic channels. Proc Natl Acad Sci U S A 2009, 106:2989–2994.
56. Mosing RK, Bowser MT. Isolating aptamers using capillary electrophoresis-SELEX (CE-SELEX). Methods Mol Biol 2009, 535:33–43.
57. Mosing RK, Mendonsa SD, Bowser MT. Capillary electrophoresis-SELEX selection of aptamers with affinity for HIV-1 reverse transcriptase. Anal Chem 2005, 77:6107–6112.
58. Eulberg D, Buchner K, Maasch C, Klussmann S. Development of an automated in vitro selection protocol to obtain RNA-based aptamers: identification of a biostable substance P antagonist. Nucleic Acids Res 2005, 33:e45.
59. Jin C, Zheng J, Li C, Qiu L, Zhang X, Tan W. Aptamers selected by cell-SELEX for molecular imaging. J Mol Evol 2015, 81:162–171.
60. Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, Meng L, Smith JE, Tan W. Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 2008, 3:991–1001.
61. Shangguan D, Cao ZC, Li Y, Tan W. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 2007, 53:1153–1155.
62. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, Cardona D, Witek RP, Liu C, Tan W. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 2008, 80:721–728.
63. Van Simaeys D, Turek D, Champanhac C, Vaizer J, Sefah K, Zhen J, Sutphen R, Tan W. Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment. Anal Chem 2014, 86:4521–4527.
64. Shi H, Tang Z, Kim Y, Nie H, Huang YF, He X, Deng K, Wang K, Tan W. In vivo fluorescence imaging of tumors using molecular aptamers generated by cell-SELEX. Chem Asian J 2010, 5:2209–2213.
65. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63:601–608.
66. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp Eye Res 2006, 83:615–619.
67. Dobrovolsky AB, Titaeva EV, Khaspekova SG, Spiridonova VA, Kopylov AM, Mazurov AV. Inhibition of thrombin activity with DNA-aptamers. Bull Exp Biol Med 2009, 148:33–36.
68. Chang JY, Chantrathammachart P, Monroe DM, Key NS. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor. Thromb Res 2012, 130:e151–e157.
69. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007, 116:2678–2686.
70. Krishnan A, Vogler EA, Sullenger BA, Becker RC. The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa. J Thromb Thrombolysis 2013, 35:48–56.
71. Reshetnikov RV, Sponer J, Rassokhina OI, Kopylov AM, Tsvetkov PO, Makarov AA, Golovin AV. Cation binding to 15-TBA quadruplex DNA is a multiple-pathway cation-dependent process. Nucleic Acids Res 2011, 39:9789–9802.
72. Soule EE, Bompiani KM, Woodruff RS, Sullenger BA. Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant. Nucleic Acid Ther 2016, 26:1–9.
73. Zavyalova E, Golovin A, Pavlova G, Kopylov A. Module-activity relationship of G-quadruplex based DNA aptamers for human thrombin. Curr Med Chem 2013, 20:4836–4843.
74. Zavyalova E, Golovin A, Reshetnikov R, Mudrik N, Panteleyev D, Pavlova G, Kopylov A. Novel modular DNA aptamer for human thrombin with high anticoagulant activity. Curr Med Chem 2011, 18:3343–3350.
75. Chen L, Li DQ, Zhong J, Wu XL, Chen Q, Peng H, Liu SQ. IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis. Osteoarthritis Cartilage 2011, 19:711–718.
76. Kaida Y, Fukami K, Matsui T, Higashimoto Y, Nishino Y, Obara N, Nakayama Y, Ando R, Toyonaga M, Ueda S, et al. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes 2013, 62:3241–3250.
77. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10:862–868.
78. Boyacioglu O, Stuart CH, Kulik G, Gmeiner WH. Dimeric DNA aptamer complexes for high-capacity-targeted drug delivery using pH-sensitive covalent linkages. Mol Ther Nucleic Acids 2013, 2:e107.
79. Wang R, Zhu G, Mei L, Xie Y, Ma H, Ye M, Qing FL, Tan W. Automated modular synthesis of aptamer-drug conjugates for targeted drug delivery. J Am Chem Soc 2014, 136:2731–2734.
80. Zhu G, Niu G, Chen X. Aptamer-drug conjugates. Bioconjug Chem 2015, 26:2186–2197.
81. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006, 103:6315–6320.
82. Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C, Tan W. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci U S A 2013, 110:7998–8003.
83. Zhu G, Meng L, Ye M, Yang L, Sefah K, O'Donoghue MB, Chen Y, Xiong X, Huang J, Song E, et al. Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J 2012, 7:1630–1636.
84. Ara MN, Matsuda T, Hyodo M, Sakurai Y, Ohga N, Hida K, Harashima H. Construction of an aptamer modified liposomal system targeted to tumor endothelial cells. Biol Pharm Bull 2014, 37:1742–1749.
85. Cai R, Yang D, Peng S, Chen X, Huang Y, Liu Y, Hou W, Yang S, Liu Z, Tan W. Single nanoparticle to 3D supercage: framing for an artificial enzyme system. J Am Chem Soc 2015, 137:13957–13963.
86. Li J, Hong CY, Wu SX, Liang H, Wang LP, Huang G, Chen X, Yang HH, Shangguan D, Tan W. Facile phase transfer and surface biofunctionalization of hydrophobic nanoparticles using Janus DNA tetrahedron nanostructures. J Am Chem Soc 2015, 137:11210–11213.
87. Li J, Mo L, Lu CH, Fu T, Yang HH, Tan W. Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications. Chem Soc Rev 2016, 45:1410–1431.
88. Li J, Zheng C, Cansiz S, Wu C, Xu J, Cui C, Liu Y, Hou W, Wang Y, Zhang L, et al. Self-assembly of DNA nanohydrogels with controllable size and stimuli-responsive property for targeted gene regulation therapy. J Am Chem Soc 2015, 137:1412–1415.
89. Liu Y, Purich DL, Wu C, Wu Y, Chen T, Cui C, Zhang L, Cansiz S, Hou W, Wang Y, et al. Ionic functionalization of hydrophobic colloidal nanoparticles to form ionic nanoparticles with enzymelike properties. J Am Chem Soc 2015, 137:14952–14958.
90. Song ZL, Chen Z, Bian X, Zhou LY, Ding D, Liang H, Zou YX, Wang SS, Chen L, Yang C, et al. Alkyne-functionalized superstable graphitic silver nanoparticles for Raman imaging. J Am Chem Soc 2014, 136:13558–13561.
91. Sung TC, Chen WY, Shah P, Chen CS. A replaceable liposomal aptamer for the ultrasensitive and rapid detection of biotin. Sci Rep 2016, 6:21369.
92. Xiong X, Wu C, Zhou C, Zhu G, Chen Z, Tan W. Responsive DNA-based hydrogels and their applications. Macromol Rapid Commun 2013, 34:1271–1283.
93. Zhang Z, Liu C, Bai J, Wu C, Xiao Y, Li Y, Zheng J, Yang R, Tan W. Silver nanoparticle gated, mesoporous silica coated gold nanorods (AuNR@MS@AgNPs): low premature release and multifunctional cancer theranostic platform. ACS Appl Mater Interfaces 2015, 7:6211–6219.
94. Huang YF, Sefah K, Bamrungsap S, Chang HT, Tan W. Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 2008, 24:11860–11865.
95. Wang J, Sefah K, Altman MB, Chen T, You M, Zhao Z, Huang CZ, Tan W. Aptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells. Chem Asian J 2013, 8:2417–2422.
96. Zhao N, You J, Zeng Z, Li C, Zu Y. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small 2013, 9:3477–3484.
97. Qin C, Fei J, Wang A, Yang Y, Li J. Rational assembly of a biointerfaced core@shell nanocomplex towards selective and highly efficient synergistic photothermal/photodynamic therapy. Nanoscale 2015, 7:20197–20210.
98. Wang G, Chen Z, Wang W, Yan B, Chen L. Chemical redox-regulated mesoporous silica-coated gold nanorods for colorimetric probing of Hg2+ and S2. Analyst 2011, 136:174–178.
99. Borghei YS, Hosseini M, Dadmehr M, Hosseinkhani S, Ganjali MR, Sheikhnejad R. Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold nanoparticles induced by DNA hybridization. Anal Chim Acta 2016, 904:92–97.
100. Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, Wong NY, Dobrucki LW, Yasui N, Katzenellenbogen JA, et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater Chem B Mater Biol Med 2013, 1:5288–5297.
101. Kang H, Trondoli AC, Zhu G, Chen Y, Chang YJ, Liu H, Huang YF, Zhang X, Tan W. Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano 2011, 5:5094–5099.
102. Wei X, Tian T, Jia S, Zhu Z, Ma Y, Sun J, Lin Z, Yang CJ. Target-responsive DNA hydrogel mediated “stop-flow” microfluidic paper-based analytic device for rapid, portable and visual detection of multiple targets. Anal Chem 2015, 87:4275–4282.
103. Yan L, Zhu Z, Zou Y, Huang Y, Liu D, Jia S, Xu D, Wu M, Zhou Y, Zhou S, et al. Target-responsive “sweet” hydrogel with glucometer readout for portable and quantitative detection of non-glucose targets. J Am Chem Soc 2013, 135:3748–3751.
104. Yang H, Liu H, Kang H, Tan W. Engineering target-responsive hydrogels based on aptamer-target interactions. J Am Chem Soc 2008, 130:6320–6321.
105. Zhu Z, Guan Z, Jia S, Lei Z, Lin S, Zhang H, Ma Y, Tian ZQ, Yang CJ. Au@Pt nanoparticle encapsulated target-responsive hydrogel with volumetric bar-chart chip readout for quantitative point-of-care testing. Angew Chem Int Ed Engl 2014, 53:12503–12507.
106. Meng H-M, Fu T, Zhang X-B, Tan W. Cell-SELEX-based aptamer-conjugated nanomaterials for theranostic applications. Natl Sci Rev 2015, 2:71–84.